TAUKLARIFY Approved
FDA Approves TAUKLARIFY Tau PET Imaging Agent for Alzheimer's Disease Diagnosis
Key Points
Study data show two large trials supporting TAUKLARIFY’s ability to identify NFT pathology: Study 1 reported positive percent agreement of 80%–88% and negative percent agreement of 98%–99%; Study 2 reported positive percent agreement of 68%–82% and negative percent agreement of 93%–99%.
FDA NDA for MK-6240 was accepted in October 2025 with a target action date of August 13, 2026 under the Prescription Drug User Fee Act, and the program had Fast Track designation to expedite development.
Preclinical development of MK-6240 began in 2016, with in vitro and animal studies showing high-affinity, selective binding to NFT-rich cortical regions and rapid, uniform brain uptake.
The safety profile across trials lists common adverse reactions including headache, nausea, injection-site reactions, dizziness and abdominal discomfort.
At the time of NDA acceptance, MK-6240 was already being used in nearly 100 active clinical trials, underscoring widespread exploratory use in Alzheimer’s research.
The FDA has approved TAUKLARIFY — a new brain-imaging drug that spots toxic protein tangles linked to Alzheimer's disease. The agent, also known as florquinitau F 18 injection or MK-6240, is now cleared for adults with cognitive impairment being evaluated for Alzheimer's, according to NeurologyLive.
The drug is made by Enigma Biomedical USA and commercialized by Lantheus Holdings, which trades on Nasdaq as LNTH. Benzinga reported shares responded to the news as Lantheus cleared a key regulatory milestone in Alzheimer's diagnostics.
What TAUKLARIFY Does and How It Works
TAUKLARIFY is a PET imaging agent. Doctors inject it before a brain scan. It binds to tau neurofibrillary tangles — clumps of a protein that build up in Alzheimer's brains and kill nerve cells. The scan shows where and how many tangles exist, according to Psychiatric Times.
Tau imaging adds a key piece of information. Doctors already use amyloid PET scans to spot a different Alzheimer's protein. TAUKLARIFY works alongside those tools — not instead of them. The FDA notes its safety and effectiveness for other tau-related brain diseases have not been established.
Two Large Studies Drove the FDA Decision
Approval rested on data from two clinical trials. Study 1 showed the drug correctly identified tau tangles in 80% to 88% of positive cases. It correctly ruled out tangles in 98% to 99% of negative cases, according to NeurologyLive.
Study 2 had slightly wider results — a positive agreement of 68% to 82% and a negative agreement of 93% to 99%. Common side effects across both trials included headache, nausea, dizziness, injection-site reactions, and abdominal discomfort. No serious safety signals stopped the approval.
A Long Road From Lab to Approval
Preclinical work on MK-6240 started in 2016. Early lab and animal studies showed the tracer binds tightly and selectively to tau-rich brain regions. It also moves into and out of the brain quickly and evenly — a key trait for a clean scan, according to Psychiatric Times.
The FDA accepted the formal drug application in October 2025, setting a target decision date of August 13, 2026 under the Prescription Drug User Fee Act. The program held Fast Track status, which sped up the review. Approval came ahead of that deadline. By the time the application was filed, MK-6240 was already running in nearly 100 active clinical trials worldwide.
Lantheus Bets Big on Alzheimer's Imaging Market
Lantheus took on TAUKLARIFY after acquiring Cerveau Technologies, the subsidiary that held commercialization rights. The company now owns both development and sales of the tracer. Seeking Alpha noted the approval as a significant win for Lantheus in the competitive Alzheimer's imaging space.
1065 The Buzz reported that the agent is injected before a brain scan to assess Alzheimer's risk. Researchers say tau imaging could push earlier detection — catching the disease before symptoms become severe. That would support a growing push to use biomarkers to speed up drug development and treatment decisions.
Sentiment
Mostly PositivePublishers
11
Articles
86
Reach
97
